Clinical and genetic studies strongly support a significant connection between nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD) and identify ASCVD as the primary cause of death in NAFLD patients. Understanding the molecular factors and mechanisms regulating these diseases is critical for developing novel therapies that target them simultaneously. Our preliminary immunoblotting experiments demonstrated elevated expression of nidogen 2 (NID2), a basement membrane glycoprotein, in human atherosclerotic vascular tissues and murine steatotic livers. Therefore, we investigated the role of NID2 in regulating hepatosteatosis and atherosclerosis utilizing Western diet-fed Apoe−/− mice with/without NID2 overexpression. Quantitative real-time PCR confirmed increased NID2 mRNA expression in multiple organs (liver, heart, kidney, and adipose) of NID2-overexpressing mice. Male mice with NID2 overexpression exhibited higher liver and epididymal white adipose tissue mass, increased hepatic lipid accumulation, and fibrosis. Additionally, these mice developed larger atherosclerotic lesions in the whole aortas and aortic roots, with increased necrotic core formation. Mechanistic studies showed reduced AMPK activation in the livers of NID2-overexpressing mice compared with controls, without any effects on hepatic inflammation. In conclusion, these findings suggest that NID2 plays a deleterious role in both hepatosteatosis and atherosclerosis, making it a potential therapeutic target for these conditions.
The clinical and genetic studies strongly support a significant connection between nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD) and identify ASCVD as the primary cause of death in NAFLD patients. Understanding the molecular factors and mechanisms regulating these diseases, is critical for developing novel therapies that target them simultaneously. Our preliminary immunoblotting experiments demonstrated elevated expression of nidogen 2 (NID2), a basement membrane glycoprotein, in human atherosclerotic vascular tissues and murine steatotic livers. Therefore, we investigated the role of NID2 in regulating hepatosteatosis and atherosclerosis utilizing Western diet-fed Apoe-/- mice with/without NID2 overexpression. Quantitative real-time PCR confirmed increased NID2 mRNA expression in multiple organs (liver, heart, kidney and adipose) of NID2-overexpressing mice. Male mice with NID2 overexpression exhibited higher liver and epididymal white adipose tissue mass, increased hepatic lipid accumulation and fibrosis. Additionally, these mice developed larger atherosclerotic lesions in the whole aortas and aortic roots, with increased necrotic core formation. Mechanistic studies showed reduced AMPK activation in the livers of NID2-overexpressing mice compared with controls, without any effects on hepatic inflammation. In conclusion, these findings suggest that NID2 plays a deleterious role in both hepatosteatosis and atherosclerosis, making it a potential therapeutic target for these conditions.
Metabolic dysfunction-associated steatotic liver disease (MASLD) primarily results from dysregulated lipid metabolism in hepatocytes. However, the mechanisms governing hepatic lipid metabolism remain incompletely understood. Our preliminary experiments demonstrated elevated expression of R-spondin 2 (RSPO2), a matricellular protein, in steatotic livers. Therefore, we investigated the role of RSPO2 in MASLD and potential underlying mechanisms. Comprehensive in vivo and in vitro studies were performed to investigate the role of RSPO2 in steatosis. Unbiased transcriptomic analyses of hepatic RNA samples were conducted to identify RSPO2-regulated signaling pathways. To examine the in vivo role of Rspo2, both hepatocyte-specific Rspo2-deficient mice and AAV-mediated Rspo2 overexpression were utilized. RSPO2 expression was significantly increased in steatotic livers of high-fat diet-fed wild-type (p <0.01) and Western diet-fed Apoe-/- mice (p <0.001). Similar results were observed with human steatotic liver tissues (p <0.01). Hepatocyte-specific deletion of Rspo2 in floxed mice, achieved either via postnatal TBG-Cre-AAV injection or embryonic Alb-Cre breeding, exacerbated diet-induced hepatic steatosis and fibrosis, suggesting that RSPO2 has protective effects against MASLD. Conversely, AAV-mediated Rspo2 overexpression in mice reduced hepatic lipid deposition (p <0.01) and decreased hepatic triglyceride and non-esterified fatty acid levels after high-rich diet feeding. Furthermore, Rspo2 overexpression suppressed hepatic fibrosis (p <0.01) and macrophage accumulation. Mechanistic studies using RNA sequencing and other techniques revealed improved lipid metabolism, increased AMPK-ACC signaling, reduced inflammation, and attenuated apoptosis in the liver with Rspo2 overexpression. In vitro experiments further demonstrated the anti-steatotic effects of recombinant RSPO2 treatment in hepatocytes. These findings identify RSPO2 as a key suppressor of hepatic steatosis and fibrosis, and highlight its potential as a therapeutic target for MASLD. Given the hepatic/extrahepatic complications associated with MASLD (metabolic dysfunction-associated steatotic liver disease) and its high prevalence, it is crucial to decipher the precise molecular mechanisms regulating its pathogenesis to identify novel druggable targets. In this study, we demonstrate for the first time that hepatocyte RSPO2 plays a protective role against hepatic steatosis, fibrosis, and inflammation. Rspo2 overexpression improves lipid metabolism, enhances AMPK-ACC signaling, and reduces hepatocyte apoptosis. Therefore, targeting RSPO2 in hepatocytes may represent a promising strategy to suppress MASLD.